Melinta Therapeutics, Inc. (NASDAQ:MLNT)

7.10
Delayed Data
As of Jun 22
 -0.35 / -4.70%
Today’s Change
5.20
Today|||52-Week Range
24.25
-55.06%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Quarter
Trend
Quarter 2
2017
Quarter 3
2017
Quarter 4
2017
Quarter 1
2018
Revenue and IncomeNet Revenues860.0K1.7M4.2M14.8M
 
 
 
 
 
Cost of Goods Sold------2.9M
 
 
Depreciation And Amortization6.0K6.0K430.0K4.8M
 
 
 
 
 
 
Operating ExpensesGross Income------7.2M
 
 
General Expenses13.2M12.2M48.5M50.8M
 
 
 
 
 
Research And Development8.5M4.4M11.6M16.1M
 
 
 
 
 
Total Operating Expenses13.2M12.3M48.9M58.4M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-12.3M-10.5M-44.7M-43.6M
 
 
 
 
 
Extraordinary Credit0.000.000.0024.1M
 
 
Extraordinary Charge-------2.6M
 
 
Interest Expense On Debt226.0K208.0K1.9M10.2M
 
 
 
 
 
Other Expenses0.000.0027.7M2.7M
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-12.3M-10.4M-18.8M-29.4M
 
 
 
 
 
Preferred Dividend0.000.00-2.1M0.00
 
 
Net Income-12.3M-10.4M-18.8M-29.4M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS10.5M10.5M14.1M30.9M
 
 
 
 
 
Shares To Calculate EPS Diluted10.5M10.5M14.1M30.9M
 
 
 
 
 
 
Earnings Per ShareEPS-$1.15-$1.00-$1.48-$0.95
 
 
 
 
 
EPS Diluted-$1.15-$1.00-$1.48-$0.95